Investors

Press Releases

Press Releases

Press Releases

August 7, 2019
– Xtampza ® ER Net Product Revenues Were $26.0 Million in the Second Quarter of 2019, a 44% Increase Over the Second Quarter of 2018 – – Cash and Cash Equivalents Increased to $148.7 Million as of June 30, 2019 , From $134.9 Million as of March 31, 2019 – – Net Loss Was $4.7 Million and Non-GAAP
May 29, 2019
STOUGHTON, Mass. , May 29, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in June: The
May 8, 2019
Xtampza ® ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter Basis Net loss of $9.7 million in the First Quarter of 2019 compared to a net loss of $18.7 million in the First Quarter of 2018
April 30, 2019
STOUGHTON, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences in May: The
April 2, 2019
STOUGHTON, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut , M.D., as the company’s first Chief Medical
April 1, 2019
STOUGHTON, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in April: The H.C.
February 27, 2019
Xtampza ® ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash and Cash Equivalents were $146.6 million as of December 31, 2018 , exceeding year-end cash guidance of $145.0 million Conference call scheduled for
January 7, 2019
– Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million – Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million – Total Operating Expenses Expected in the Range of $125 Million to $135 Million STOUGHTON, Mass. , Jan.